Large-scale analysis investigates serologic and demographic patterns in MOGAD and AQP4+NMOSD, suggesting important insights for clinical practices.
Large-scale studies examining the demographic, serologic, and seasonal characteristics of myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) and aquaporin-4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) remain limited, despite their potential to provide crucial information for resource allocation, clinical trial design, and recruitment. The goals of this study were to investigate demographic, serologic, and seasonal variations in MOGAD and AQP4+NMOSD using a large neuroimmunology laboratory registry validated by clinical cohorts.
No takes yet. Share an insight, caveat, or question.
Vorasoot et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: